The George Institute for Global Health, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
The George Institute for Global Health, Sydney, Australia.
Am J Kidney Dis. 2016 Jul;68(1):94-102. doi: 10.1053/j.ajkd.2016.01.020. Epub 2016 Mar 3.
The kidney-brain interaction has been a topic of growing interest. Past studies of the effect of kidney function on intracerebral hemorrhage (ICH) outcomes have yielded inconsistent findings. Although the second, main phase of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) suggests the effectiveness of early intensive blood pressure (BP) lowering in improving functional recovery after ICH, the balance of potential benefits and harms of this treatment in those with decreased kidney function remains uncertain.
Secondary analysis of INTERACT2, which randomly assigned patients with ICH with elevated systolic BP (SBP) to intensive (target SBP<140mmHg) or contemporaneous guideline-based (target SBP<180mmHg) BP management.
SETTING & PARTICIPANTS: 2,823 patients from 144 clinical hospitals in 21 countries.
Admission estimated glomerular filtration rates (eGFRs) of patients were categorized into 3 groups based on the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation: normal or high, mildly decreased, and moderately to severely decreased (>90, 60-90, and <60mL/min/1.73m(2), respectively).
The effect of admission eGFR on the primary outcome of death or major disability at 90 days (defined as modified Rankin Scale scores of 3-6) was analyzed using a multivariable logistic regression model. Potential effect modification of intensive BP lowering treatment by admission eGFR was assessed by interaction terms.
Of 2,623 included participants, 912 (35%) and 280 (11%) had mildly and moderately/severely decreased eGFRs, respectively. Patients with moderately/severely decreased eGFRs had the greatest risk for death or major disability at 90 days (adjusted OR, 1.82; 95% CI, 1.28-2.61). Effects of early intensive BP lowering were consistent across different eGFRs (P=0.5 for homogeneity).
Generalizability issues arising from a clinical trial population.
Decreased eGFR predicts poor outcome in acute ICH. Early intensive BP lowering provides similar treatment effects in patients with ICH with decreased eGFRs.
肾脏-大脑的相互作用一直是一个备受关注的话题。过去研究肾功能对脑出血(ICH)预后的影响得出的结果并不一致。尽管急性脑出血强化降压试验(INTERACT2)的第二阶段,即主要阶段,表明早期积极降压治疗在改善 ICH 后功能恢复方面的有效性,但在肾功能下降的患者中,这种治疗的潜在益处和危害之间的平衡仍不确定。
INTERACT2 的二次分析,该分析将 SBP 升高的 ICH 患者随机分为强化(目标 SBP<140mmHg)或同期基于指南的(目标 SBP<180mmHg)血压管理。
来自 21 个国家的 144 家临床医院的 2823 名患者。
根据 CKD-EPI(慢性肾脏病流行病学合作)肌酐方程,将患者的入院时估计肾小球滤过率(eGFR)分为 3 组:正常或高、轻度降低和中度至重度降低(分别为>90、60-90 和<60mL/min/1.73m(2))。
采用多变量逻辑回归模型分析入院时 eGFR 对 90 天主要结局(定义为改良Rankin 量表评分 3-6)的影响。通过交互项评估强化降压治疗对入院时 eGFR 的潜在效应修饰作用。
在纳入的 2623 名参与者中,912 名(35%)和 280 名(11%)患者的 eGFR 分别为轻度和中度/重度降低。中度/重度 eGFR 降低的患者在 90 天时死亡或重度残疾的风险最高(调整后的 OR,1.82;95%CI,1.28-2.61)。早期强化降压的效果在不同 eGFR 之间是一致的(P=0.5 用于同质性)。
临床试验人群中出现的推广问题。
eGFR 降低预测急性 ICH 预后不良。早期积极降压治疗对 eGFR 降低的 ICH 患者具有相似的治疗效果。